Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ozer

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Rheumatology (Oxford, England)|April 1, 2008
PTPN22 gene polymorphism in Takayasu's arteritisN Sahin, K Aksu, S Kamali, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory responseMuller Fabbri, Alessio Paone, Federica Calore, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Neuro-Oncology|May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cellsMorgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Acta Neuropathologica|May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumorsAndrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled TrialByram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Nature Communications|January 7, 2023
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformationZachary A Hing, Janek S Walker, Ethan C Whipp, et al.
Journal of Neuro-Oncology|March 1, 2024
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumorsJames L Rogers, Thomas Wall, Alvina A Acquaye-Mallory, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Rheumatology (Oxford, England)|April 1, 2008
PTPN22 gene polymorphism in Takayasu's arteritisN Sahin, K Aksu, S Kamali, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2012
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory responseMuller Fabbri, Alessio Paone, Federica Calore, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Neuro-Oncology|May 28, 2025
Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cellsMorgan J Coombs, Tyrone Dowdy, Md Masud Alam, et al.
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Acta Neuropathologica|May 17, 2024
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumorsAndrew L Lin, Vasilisa A Rudneva, Allison L Richards, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled TrialByram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Nature Communications|January 7, 2023
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformationZachary A Hing, Janek S Walker, Ethan C Whipp, et al.
Journal of Neuro-Oncology|March 1, 2024
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumorsJames L Rogers, Thomas Wall, Alvina A Acquaye-Mallory, et al.
Pageof 22